IDH1andIDH2Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

Warburg, 1956, On respiratory impairment in cancer cells, Science, 124, 269, 10.1126/science.124.3215.269

Hsu, 2008, Cancer cell metabolism: Warburg and beyond, Cell, 134, 703, 10.1016/j.cell.2008.08.021

Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809

Oermann, 2012, Alterations of metabolic genes and metabolites in cancer, Semin Cell Dev Biol, 23, 370, 10.1016/j.semcdb.2012.01.013

Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382

Balss, 2008, Analysis of the IDH1 codon 132 mutation in brain tumors, Acta Neuropathologica, 116, 597, 10.1007/s00401-008-0455-2

Bleeker, 2009, IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors, Hum Mutat, 30, 7, 10.1002/humu.20937

Hartmann, 2009, Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas, Acta Neuropathologica, 118, 469, 10.1007/s00401-009-0561-9

Ichimura, 2009, IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas, Neuro Oncol, 11, 341, 10.1215/15228517-2009-025

Korshunov, 2009, Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma, Acta Neuropathologica, 118, 401, 10.1007/s00401-009-0550-z

Sanson, 2009, Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas, J Clin Oncol, 27, 4150, 10.1200/JCO.2009.21.9832

Watanabe, 2009, IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas, Am J Pathol, 174, 1149, 10.2353/ajpath.2009.080958

Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med, 360, 765, 10.1056/NEJMoa0808710

Dang, 2010, IDH mutations in glioma and acute myeloid leukemia, Trends Mol Med, 16, 387, 10.1016/j.molmed.2010.07.002

Gravendeel, 2010, Segregation of non-p.R132H mutations inIDH1 in distinct molecular subtypes of glioma, Hum Mutat, 31, E1186, 10.1002/humu.21201

Mardis, 2009, Recurring mutations found by sequencing an acute myeloid leukemia genome, N Engl J Med, 361, 1058, 10.1056/NEJMoa0903840

Marcucci, 2011, Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications, J Clin Oncol, 29, 475, 10.1200/JCO.2010.30.2554

Chou, 2010, Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation, Blood, 115, 2749, 10.1182/blood-2009-11-253070

Gross, 2010, Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations, J Exp Med, 207, 339, 10.1084/jem.20092506

Ho, 2010, Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study, Leukemia, 24, 909, 10.1038/leu.2010.56

Marcucci, 2010, IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study, J Clin Oncol, 28, 2348, 10.1200/JCO.2009.27.3730

Tefferi, 2010, IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis, Leukemia, 24, 1302, 10.1038/leu.2010.113

Wagner, 2010, Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor, J Clin Oncol, 28, 2356, 10.1200/JCO.2009.27.6899

Ward, 2010, The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate, Cancer Cell, 17, 225, 10.1016/j.ccr.2010.01.020

Hemerly, 2010, Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas, Eur J Endocrinol, 163, 747, 10.1530/EJE-10-0473

Murugan, 2010, Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer, Biochem Biophys Res Commun, 393, 555, 10.1016/j.bbrc.2010.02.095

Amary, 2011, IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours, J Pathol, 224, 334, 10.1002/path.2913

Amary, 2011, Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2, Nat Genet, 43, 1262, 10.1038/ng.994

Pansuriya, 2011, Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome, Nat Genet, 43, 1256, 10.1038/ng.1004

Wang, 2012 23, Mutations in isocitrate dehydrogenase 1 and 2 are associated with DNA hypermethylation in intrahepatic cholangiocarcinomas, Oncogene

Borger, 2012, Frequent mutation of isocitrate dehydrogenase (IDH) 1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping, Oncologist, 17, 72, 10.1634/theoncologist.2011-0386

Kang, 2009, Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers, Int J Cancer, 125, 353, 10.1002/ijc.24379

Gaal, 2010, Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas, J Clin Endocrinol Metab, 95, 1274, 10.1210/jc.2009-2170

Lopez, 2010, IDH1R132 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain, Biochem Biophys Res Commun, 398, 585, 10.1016/j.bbrc.2010.06.125

Kranendijk, 2010, IDH2 mutations in patients with D-2-hydroxyglutaric aciduria, Science, 330, 336, 10.1126/science.1192632

Pusch, 2011, Glioma IDH1 mutation patterns off the beaten track, Neuropathol Appl Neurobiol, 37, 428, 10.1111/j.1365-2990.2010.01127.x

Patel, 2012, Prognostic relevance of integrated genetic profiling in acute myeloid leukemia, N Engl J Med, 366, 1079, 10.1056/NEJMoa1112304

Seltzer, 2010, Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1, Cancer Res, 70, 8981, 10.1158/0008-5472.CAN-10-1666

Bralten, 2011, IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo, Ann Neurol, 69, 455, 10.1002/ana.22390

Zhao, 2009, Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 {alpha}, Science, 324, 261, 10.1126/science.1170944

Dang, 2009, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, 462, 739, 10.1038/nature08617

Xu, 2011, Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases, Cancer Cell, 19, 17, 10.1016/j.ccr.2010.12.014

Figueroa, 2010, Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, Cancer Cell, 18, 553, 10.1016/j.ccr.2010.11.015

Ward, 2012, Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production, Oncogene, 31, 2491, 10.1038/onc.2011.416

Amary, 2011, Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2, Nat Genet, 43, 1262, 10.1038/ng.994

Elkhaled, 2012, Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas, Sci Transl Med, 4, 116ra5, 10.1126/scitranslmed.3002796

Pope, 2012, Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy, J Neurooncol, 107, 197, 10.1007/s11060-011-0737-8

Kalinina, 2012, Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma, J Mol Med (Berl), 90, 1161, 10.1007/s00109-012-0888-x

Choi, 2012, 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas, Nat Med, 18, 624, 10.1038/nm.2682

Andronesi, 2012, Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy, Sci Transl Med, 4, 116ra4, 10.1126/scitranslmed.3002693

Achouri, 2004, Identification of a dehydrogenase acting on D-2-hydroxyglutarate, Biochem J, 381, 35, 10.1042/BJ20031933

Topçu, 2004, L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22. 1, Hum Mol Genet, 13, 2803, 10.1093/hmg/ddh300

Struys, 2005, Kinetic characterization of human hydroxyacid–oxoacid transhydrogenase: Relevance to, J Inherit Metab Dis, 28, 921, 10.1007/s10545-005-0114-x

Rzem, 2007, L-2-hydroxyglutaric aciduria, a defect of metabolite repair, J Inherit Metab Dis, 30, 681, 10.1007/s10545-007-0487-0

Chalmers, 1980, D-2-Hydroxyglutaric aciduria: case report and biochemical studies, J Inherit Metab Dis, 3, 11, 10.1007/BF02312516

Duran, 1980, L-2-Hydroxyglutaric aciduria: an inborn error of metabolism?, J Inherit Metab Dis, 3, 109, 10.1007/BF02312543

Kranendijk, 2012, Progress in understanding 2-hydroxyglutaric acidurias, J Inherit Metab Dis, 1

Atai, 2011, Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma, J Histochem Cytochem, 59, 489, 10.1369/0022155411400606

Jin, 2011, 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP+-dependent isocitrate dehydrogenase mutations, PLoS ONE, 6, e16812, 10.1371/journal.pone.0016812

Metallo, 2012, Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia, Nature, 481, 380, 10.1038/nature10602

Mullen, 2012, Reductive carboxylation supports growth in tumour cells with defective mitochondria, Nature, 481, 385, 10.1038/nature10642

Wise, 2011, Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability, Proc Natl Acad Sci, 108, 19611, 10.1073/pnas.1117773108

Mussini, 1967, Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth, Science, 157, 927, 10.1126/science.157.3791.927

Iyer, 2009, Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids, Cell Cycle, 8, 1698, 10.4161/cc.8.11.8580

Hausinger, 2004, FeII/alpha-ketoglutarate-dependent hydroxylases and related enzymes, Crit Rev Biochem Mol Biol, 39, 21, 10.1080/10409230490440541

Loenarz, 2008, Expanding chemical biology of 2-oxoglutarate oxygenases, Nat Chem Biol, 4, 152, 10.1038/nchembio0308-152

Rose, 2011, Inhibition of 2-oxoglutarate dependent oxygenases, Chem Soc Rev, 40, 4364, 10.1039/c0cs00203h

Clifton, 2006, Structural studies on 2-oxoglutarate oxygenases and related double-stranded beta-helix fold proteins, J Inorg Biochem, 100, 644, 10.1016/j.jinorgbio.2006.01.024

Chowdhury, 2011, The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases, EMBO Rep, 12, 463, 10.1038/embor.2011.43

Lu, 2012, IDH mutation impairs histone demethylation and results in a block to cell differentiation, Nature, 483, 474, 10.1038/nature10860

Yan, 2009, Mutant metabolic enzymes are at the origin of gliomas, Cancer Res, 69, 9157, 10.1158/0008-5472.CAN-09-2650

Kriaucionis, 2009, The nuclear DNA base 5-hydroxymethylcytosine is present in purkinje neurons and the brain, Science, 324, 929, 10.1126/science.1169786

Tahiliani, 2009, Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1, Science, 324, 930, 10.1126/science.1170116

Verhaak, 2010, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, 17, 98, 10.1016/j.ccr.2009.12.020

Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell, 17, 510, 10.1016/j.ccr.2010.03.017

Turcan, 2012, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, Nature, 483, 479, 10.1038/nature10866

Capper, 2010, Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors, Brain Pathol, 20, 245, 10.1111/j.1750-3639.2009.00352.x

Capper, 2009, Monoclonal antibody specific for IDH1 R132H mutation, Acta Neuropathol, 118, 599, 10.1007/s00401-009-0595-z

Capper, 2011, Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology, Acta Neuropathol, 121, 241, 10.1007/s00401-010-0770-2

Horbinski, 2009, Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues, J Neuropathol Exp Neurol, 68, 1319, 10.1097/NEN.0b013e3181c391be

Capper, 2010, Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes, Am J Surg Pathol, 34, 1199, 10.1097/PAS.0b013e3181e7740d

Horbinski, 2011, Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas, Brain Pathol, 21, 564, 10.1111/j.1750-3639.2011.00480.x

Camelo-Piragua, 2011, A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53, J Neuropathol Exp Neurol, 70, 110, 10.1097/NEN.0b013e31820565f9

Sanson, 2009, Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas, J Clin Oncol, 27, 4150, 10.1200/JCO.2009.21.9832

Thon, 2012, IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival, Cancer, 118, 452, 10.1002/cncr.26298

Chou, 2011, The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia, Leukemia, 25, 246, 10.1038/leu.2010.267

Dunn, 2012, Emerging insights into the molecular and cellular basis of glioblastoma, Genes Dev, 26, 756, 10.1101/gad.187922.112

Watanabe, 2009, IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas, Am J Pathol, 174, 1149, 10.2353/ajpath.2009.080958

Labussiere, 2010, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2, Neurology, 74, 1886, 10.1212/WNL.0b013e3181e1cf3a

Sahm, 2012, CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas, Acta Neuropathol, 123, 853, 10.1007/s00401-012-0993-5

Bettegowda, 2011, Mutations in CIC and FUBP1 contribute to human oligodendroglioma, Science, 333, 1453, 10.1126/science.1210557

Yip, 2012, Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers, J Pathol, 226, 7, 10.1002/path.2995

Abbas, 2010, Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value, Blood, 116, 2122, 10.1182/blood-2009-11-250878

Shen, 2011, Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia, Blood, 118, 5593, 10.1182/blood-2011-03-343988

Luchman, 2012, An in vivo patient-derived model of endogenous IDH1-mutant glioma, Neuro Oncol, 14, 184, 10.1093/neuonc/nor207

Sasaki, 2012, IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics, Nature, 488, 656, 10.1038/nature11323